Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Motif Bio Plc (MTFB : NSDQ)

• Company Description    Motif Bio plc is a biopharmaceutical company. It engaged in the research and development of antibiotics for serious and life-threatening infections caused by multi-drug resistant bacteria. The company's product pipeline includes Iclaprim, REVIVE-1 and REVIVE-2 which are in clinical stage. Motif Bio plc is headquartered in London, UK. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $ Daily Weekly Monthly 20 Day Moving Average: shares Shares Outstanding: (millions) Market Capitalization: $ (millions) Beta: 52 Week High: $11.50 52 Week Low: $0.08 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week % % 12 Week % % Year To Date % %

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 201 TEMPLE CHAMBERS 3-7 TEMPLE AVENUE - LONDON,X0 EC4Y 0DT GBR ph: 212-210-6248 fax: - ir@motifbio.com http://www.motifbio.com

• General Corporate Information    Officers Bruce Williams - Chairman Jonathan E. Gold - President and Chief Business Officer Graham Lumsden - Director Christopher Wardhaugh - Director Mary Lake Polan - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 619784101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: Most Recent Split Date: (:1) Beta: Market Capitalization: $ (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: % Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/25 - - 12/31/24 - - 09/30/24 - - ROA 03/31/25 - - 12/31/24 - - 09/30/24 - - Current Ratio 03/31/25 - - 12/31/24 - - 09/30/24 - - Quick Ratio 03/31/25 - - 12/31/24 - - 09/30/24 - - Operating Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Net Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Pre-Tax Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Book Value 03/31/25 - - 12/31/24 - - 09/30/24 - - Inventory Turnover 03/31/25 - - 12/31/24 - - 09/30/24 - - Debt-to-Equity 03/31/25 - - 12/31/24 - - 09/30/24 - - Debt-to-Capital 03/31/25 - - 12/31/24 - - 09/30/24 - -

Powered by Zacks Investment Research ©